MedPath

Study of the Effects of a New Infant Formula Supplemented With a Probiotic Over the Corporal Composition of Infants

Not Applicable
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Nutribén®
Dietary Supplement: Breastfeed
Dietary Supplement: Nutribén Innova® 1
Registration Number
NCT05303077
Lead Sponsor
Alter Farmacia, S.A.
Brief Summary

This is a multicentric, randomized, blinded, controlled trial to study the effects of a new infant formula on the changes in the newborn body composition over time: weight gain, anthropometric data, incidence of infections, digestive tolerance (flatulence, vomiting and regurgitation), feces (consistency and frequency), behavior (restlessness, colic, nocturnal awakenings), count of probiotic strains of the intestinal microbiota in feces, safety and tolerability of the investigational products (measured as number, frequency and severity of adverse events in all branches of the study)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
210
Inclusion Criteria
  • Healthy children. Both sex.
  • Full term infants (between 37 and 42 weeks of pregnancy).
  • Birth weight between 2500 g- 4500 g.
  • Single birth babies.
  • BMI of the mothers before the pregnancy between 19 y 30 kg/m2.
Exclusion Criteria
  • Body weight lower than the 5th percentile for their gestational age.
  • Cow's milk protein allergy and/or lactose allergy.
  • Administration of antibiotics 7 days prior inclusion.
  • Congenital disease or malformation that may affect the infant growth rate.

Population Description: The study population are newborns selected from primary care clinics in Spain.

Sampling Method: Not applicable

  • Metabolic disease or disorders.
  • Significant prenatal disease and/or serious postnatal disease before recruitment.
  • Underage parents.
  • Diabetic mother.
  • Born from a drug abuse mother (who use abuse drugs during pregnancy).
  • Parents cannot comply with study procedures.
  • Subject included or that have been included in other clinical trial since his/her birth day.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Infant FormulaNutribén®Infant formula
Breastfeed Active comparatorBreastfeedInfants who are breastfed
Study Infant FormulaNutribén Innova® 1Infant formula supplemented with omega 3 fatty acids and inactive Bifidobacteria
Primary Outcome Measures
NameTimeMethod
Weight gain at 6 months6 months after the beginning of the study

Measure of weight gain by grams/day between the first visit and month 6

Secondary Outcome Measures
NameTimeMethod
weight at 21 days, 2, 4, 6 and 12 months21 days, 2, 4, 6 and 12 months

Measure of weight gain by grams

Length gain21 days, 2, 4, 6 and 12 months

Measure of the infant's length gain over time in cms

Head circumference gain21 days, 2, 4, 6 and 12 months

Measure of the increase of the head circumference over time in cms

Feces features consistency21 days, 2, 4, 6 and 12 months

Description of the consistency of baby's feces features, according to their parent's perception, on a qualitative scale: soft, hard, liquid, normal, semiliquid, pasty. The analysis includes the number of feces in each group and the overall frequency by study arm and visit.

Evolution of calprotectin levels in feces21 days, 2, 6 and 12 months

Measurement of the evolution of calprotectin levels in feces over time

Evolution of IgA levels in feces21 days, 2, 6 and 12 months

Measurement of the evolution of IgA levels in feces over time

Evolution lactic acid levels in feces21 days, 2, 6 and 12 months

Measurement of the evolution of lactic acid levels in feces over time

Overall rate of the products2, 4, 6 and 12 months

Quantitative variable. The parents' subjective rate of the products. The assessment can be, acceptable, good, very good, satisfactory or not satisfactory.

Mean arm circumference4, 6 and 12 months

Measure of arm circumference over time in cms.

Feces features number of bowel movements21 days, 2, 4, 6 and 12 months

Number of bowel movements per day sorted by study group

Digestive tolerance4, 6 and 12 months

The digestive tolerance will be assessed as adequate, constipation, flatulence, vomit or other distresses, which are a heterogeneous group that includes various affections as diarrhea, abdominal pain, irritability, constipation, regurgitation or colic. The analysis includes the overall number and the frequency sorted by study arm.

intestinal microbiota4, 6 and 12 months

Analysis of the evolution of the intestinal microbiota of the children over the study. The richness and diversity of the microbiota are analyzed and compared between the study groups.

Infant's behavior4, 6 and 12 months

Qualitative variable. The infant's behavior is classified as either good or altered. The total number and the relative frequency by group are included in the analysis.

Evolution of short-chain fatty acid levels in feces21 days, 2, 6 and 12 months

Measurement of the evolution of short-chain fatty acid levels in feces over time

Morbilityover a year

Analysis of the number and frequency of all adverse events registered during the study by feeding group

Products Tolerabilityover a year

Quantitative variable. The tolerability of the products is assessed as adequate, good, very good, unsatisfactory. The analysis includes the overall number y and the relative frequency by group.

Tricipital Skin fold development4, 6 and 12 months

Measurement of the development of tricipital skin fold, in cms, measured using a skinfold caliper

Subscapular skin fold develompent4, 6 and 12 months

Measurement of the development of subscapular skin fold, in cms, measured using a skinfold caliper

Trial Locations

Locations (21)

Cs Amante Laffón

🇪🇸

Sevilla, Spain

Cap Montclar

🇪🇸

Barcelona, Spain

Cap Nova Lloreda

🇪🇸

Barcelona, Spain

Consultorio Arroyomolinos (Cs Parque Coimbra)

🇪🇸

Madrid, Spain

Cap Sant Ildefons

🇪🇸

Barcelona, Spain

Consulta Dr. Xavier Riopedre

🇪🇸

Barcelona, Spain

Consulta Carlos Nuñez de Prado Aparicio

🇪🇸

Madrid, Spain

Cs Alcalde Bartolomé Gonzalez Móstoles

🇪🇸

Madrid, Spain

Cs Dr Luengo Rodríguez

🇪🇸

Madrid, Spain

Cs Infante Don Luis de Borbón

🇪🇸

Madrid, Spain

Consultas Externas Hospital Privado Santa Ángela de La Cruz

🇪🇸

Sevilla, Spain

Cs Miguel Servet

🇪🇸

Madrid, Spain

Cs Conde de Barcelona

🇪🇸

Madrid, Spain

Cs Presentación Sabio

🇪🇸

Madrid, Spain

Cs La Rivota

🇪🇸

Madrid, Spain

Cs Las Américas

🇪🇸

Madrid, Spain

Cs Parque Loranca

🇪🇸

Madrid, Spain

Cs Valle de La Oliva

🇪🇸

Madrid, Spain

Clínica Dr Aguilar-Dr Sacristán

🇪🇸

Sevilla, Spain

Cs Utrera Norte

🇪🇸

Sevilla, Spain

Ihp Bellavista

🇪🇸

Sevilla, Spain

© Copyright 2025. All Rights Reserved by MedPath